- Vancouver, Canada-based Precision NanoSystems (PNI) provides technology solutions enabling the development and manufacturing of lipid nanoparticles for the delivery of genetic medicines, including mRNA
- PNI will join Danaher’s Life Sciences platform, complementing the portfolios of Cytiva and Pall
June 1, 2021
Precision NanoSystems (PNI) has been acquired by Danaher Corporation’s Life Sciences platform. PNI is a global leader in technologies and solutions for the development of genetic medicines, including mRNA vaccines and therapeutics. PNI will join Danaher’s Life Sciences platform and will be complementary to other businesses in the platform, including Cytiva and Pall.